Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHENO-MEDs: Phenotype-Guided Obesity Pharmacotherapy
NCT03374956Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2017
- Primary completion
- May 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of phentermine, topiramate, liraglutide, naltrexone, bupropion in obesity, sponsored by Mayo Clinic. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03374956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374956.